

Washington, DC 20477, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: September 11, 2000.

**Bob Sargis,**

*Reports Clearance Officer.*

[FR Doc. 00-23709 Filed 9-14-00; 8:45 am]

BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Request for Nominations for Nonvoting Members of Industry Interests on Public Advisory Committees; Extension of Nomination Period

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of nomination period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending the nomination period for nonvoting representatives of industry interests to serve on public advisory committees under the purview of the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). This request for nominations was announced in the **Federal Register** of August 16, 2000 (65 FR 49990). FDA has been asked to extend the nominations period to allow additional time for the submission of nominations. Note also that the street address for the CBER contact person has been changed.

**DATES:** Nominations should be received by October 16, 2000.

**ADDRESSES:** All nominations for representatives should be sent to William Freas or John M. Treacy (addresses below).

#### FOR FURTHER INFORMATION CONTACT:

Regarding representatives of industry interests for CBER advisory committees: William Freas, Scientific Advisors and Consultants Staff (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, FAX: 301-827-0294, or e-mail: FREAS@CBER.FDA.GOV.

Regarding representatives of industry interests for CDER advisory committees: John M. Treacy, Advisors and Consultants Staff (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, or e-mail: TREACY@CDER.FDA.GOV.

Dated: September 12, 2000.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 00-23880 Filed 9-13-00; 1:36 pm]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Antiviral Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Antiviral Drugs Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on October 16, 2000, 8:30 a.m. to 5 p.m.

*Location:* Marriott Washingtonian Center, the Ballrooms, 9751 Washingtonian Blvd., Gaithersburg, MD.

*Contact Person:* Nancy Chamberlin or Beverly O'Neil, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-7001, or by e-mail: CHAMBERLINN@CDER.FDA.GOV, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12531. Please call the Information Line

for up-to-date information on this meeting.

*Agenda:* The committee will discuss the use of surrogate markers in the early development of immunomodulatory agents for the treatment of patients with human immunodeficiency virus (HIV).

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 2, 2000. Oral presentations from the public will be scheduled between approximately 1 p.m. to 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 2, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 23, 2000.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 00-23798 Filed 9-14-00; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 00N-1394]

#### Medical Devices; CLIA Waiver Criteria; Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; extension of comment period.

**SUMMARY:** The Food and Drug Administration (FDA) is extending to October 16, 2000, the comment period for the notice of a public workshop that appeared in the **Federal Register** of July 21, 2000 (65 FR 45384). That notice announced FDA's intention to review the criteria used to determine whether specific laboratory tests are waived from certain requirements of the Clinical Laboratory Improvement Amendments of 1988 (CLIA). This extension of the comment period is intended to allow interested persons additional time to submit comments on the CLIA waiver criteria.

**DATES:** Submit written comments by October 16, 2000.